EP 4103208 A1 20221221 - RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER
Title (en)
RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER
Title (de)
REKOMBINANTE THERAPEUTISCHE INTERVENTIONEN FÜR KREBS
Title (fr)
INTERVENTIONS THÉRAPEUTIQUES RECOMBINANTES CONTRE LE CANCER
Publication
Application
Priority
- US 202016790161 A 20200213
- US 2021018007 W 20210212
Abstract (en)
[origin: WO2021163602A1] Described are methods of suppressing the expression of myeloid-derived suppressor cells (MDSCs), M2 macrophages, and Treg cells in a tumor and inducing the expression of macrophages, dendritic cells (DCs), and T effector cells in a tumor in a subject. A pharmaceutical composition comprising a strain of Mycobacteria including an expression vector of the present invention is administered to a subject.
IPC 8 full level
A61K 35/74 (2015.01); A61K 39/04 (2006.01); A61K 39/39 (2006.01); C12N 15/70 (2006.01)
CPC (source: EP)
A61K 35/74 (2013.01); A61K 39/04 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2017.12); C12N 15/70 (2013.01); C12N 15/74 (2013.01); A61K 2039/523 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55594 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021163602 A1 20210819; AU 2021220986 A1 20220901; CA 3167223 A1 20210819; CN 115443143 A 20221206; EP 4103208 A1 20221221; EP 4103208 A4 20240508; JP 2023514553 A 20230406
DOCDB simple family (application)
US 2021018007 W 20210212; AU 2021220986 A 20210212; CA 3167223 A 20210212; CN 202180028637 A 20210212; EP 21754580 A 20210212; JP 2022547296 A 20210212